Urban Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

Urban Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$23K	Buy	+108	New	+$22.7K	0.08%	137

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Urban Wealth Management's BTAI Position: Q2 2022 in Review

Urban Wealth Management opened a new position in BioXcel Therapeutics (BTAI) in Q2 2022: 108 shares worth $23K. The stake represents 0.08% of the portfolio and ranks #137 among its holdings.

94 funds tracked by Wall St. Rank hold BTAI as of Q2 2022.

Urban Wealth Management held 108 shares of BioXcel Therapeutics worth $23K as of Q2 2022.
BioXcel Therapeutics was a new Urban Wealth Management position in Q2 2022.
BioXcel Therapeutics made up 0.08% of Urban Wealth Management's portfolio in Q2 2022, its #137 holding.
94 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.